Search Results - "Beary, John F."

Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis by Delmas, Pierre D, McClung, Michael R, Zanchetta, José R, Racewicz, Artur, Roux, Christian, Benhamou, Claude-Laurent, Man, Zulema, Eusebio, Rachelle A, Beary, John F, Burgio, David E, Matzkin, Ellen, Boonen, Steven

“…Abstract Introduction: Risedronate has been shown to be effective in the treatment of postmenopausal osteoporosis when given orally in daily or weekly doses or…”
Get full text

Comparison of the effects of once-monthly versus once-daily risedronate in postmenopausal osteoporosis: A phase II, 6-month, multicenter, randomized, double-blind, active-controlled, dose-ranging study by Ste-Marie, Louis-Georges, MD, Brown, Jacques P., MD, Beary, John F., MD, Matzkin, Ellen, MD, Darbie, Lynn M., MS, Burgio, David E., PhD, Racewicz, Artur J., MD

“…Abstract Background: Risedronate 5 mg/d is approved by the US Food and Drug Administration for the treatment and prevention of postmenopausal osteoporosis…”
Get full text

Risk factors associated with the loss of cartilage volume on weight-bearing areas in knee osteoarthritis patients assessed by quantitative magnetic resonance imaging: a longitudinal study by Pelletier, Jean-Pierre, Raynauld, Jean-Pierre, Berthiaume, Marie-Josée, Abram, François, Choquette, Denis, Haraoui, Boulos, Beary, John F, Cline, Gary A, Meyer, Joan M, Martel-Pelletier, Johanne

“…The objective of this study was to identify, on a symptomatic knee osteoarthritis (OA) cohort, the risk factors associated with the progression of the disease…”
Get full text

Long term evaluation of disease progression through the quantitative magnetic resonance imaging of symptomatic knee osteoarthritis patients: correlation with clinical symptoms and radiographic changes by Raynauld, Jean-Pierre, Martel-Pelletier, Johanne, Berthiaume, Marie-Josée, Beaudoin, Gilles, Choquette, Denis, Haraoui, Boulos, Tannenbaum, Hyman, Meyer, Joan M, Beary, John F, Cline, Gary A, Pelletier, Jean-Pierre

“…The objective of this study was to further explore the cartilage volume changes in knee osteoarthritis (OA) over time using quantitative magnetic resonance…”
Get full text

Effect of risedronate on joint structure and symptoms of knee osteoarthritis: results of the BRISK randomized, controlled trial [ISRCTN01928173] by Spector, Tim D, Conaghan, Philip G, Buckland-Wright, J Christopher, Garnero, Patrick, Cline, Gary A, Beary, John F, Valent, David J, Meyer, Joan M

“…To determine the efficacy and safety of risedronate in patients with knee osteoarthritis (OA), the British study of risedronate in structure and symptoms of…”
Get full text

Comparison of fixed flexion, fluoroscopic semi-flexed and MTP radiographic methods for obtaining the minimum medial joint space width of the knee in longitudinal osteoarthritis trials by Cline, G.A., Meyer, J.M., Stevens, R., Buckland-Wright, C., Peterfy, C., Beary, John F.

“…To compare three radiographic techniques (fluoroscopic semi-flexed [Fluoro], fixed flexion [FF], and semi-flexed metatarsophalangeal joint [MTP] views) for…”
Get full text

The CERT concept: an industry perspective by Beary, 3rd, J F

Get more information

Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: Results of the two‐year multinational knee osteoarthritis structural arthritis study by Bingham, Clifton O., Buckland‐Wright, J. Chris, Garnero, Patrick, Cohen, Stanley B., Dougados, Maxime, Adami, Silvano, Clauw, Daniel J., Spector, Timothy D., Pelletier, Jean‐Pierre, Raynauld, Jean‐Pierre, Strand, Vibeke, Simon, Lee S., Meyer, Joan M., Cline, Gary A., Beary, John F.

“…Objective Bisphosphonates have slowed the progression of osteoarthritis (OA) in animal models and have decreased pain in states of high bone turnover. The Knee…”
Get full text

More Conflicts of Interest: Review Articles Sponsored by the Pharmaceutical Industry-Reply by Beary, John F

“…In Reply.—Dr Nahata suggests that honoraria received in support of writing review articles be disclosed as part of the biomedical publishing process.The…”
Get full text

Inappropriate Drug Prescribing by Beary, John F

“…To the Editor.—Dr Willcox and colleagues1 call attention to the need for better education in geriatric pharmacology and improved prescribing practices in the…”
Get full text

Food and Drug Administration centennial: Recognizing the guardians of our drug supply by Beary, John F.

Get full text

Combined Care of the Rheumatic Patient by Beary, John F

“…This book is a delight to read. Its theme is the multidisciplinary care of patients with rheumatic disease.The book is organized around three sections. Section…”
Get full text

Manual of rheumatology and outpatient orthopedic disorders: diagnosis and therapy / Division of Rheumatic Diseases, Department of Orthopedic Surgery, Hospital for Special Surgery, Cornell University Medical College, New York City ; edited by Stephen Paget, Paul Pellicci, John F. Beary III : forewords by John L. Decker, Graham R.V. Hughes by Paget, Stephen A, Pellicci, Paul, Beary, John F

Get more information

Confusion about Drug Names by Huseby, Jon S, Anderson, Paul, Beary, John F

“…To the Editor: A 77-year-old woman with chronic renal failure, glaucoma, and a history of mild dementia was hospitalized for evaluation and treatment of volume…”
Get full text

Romatoloji ve klinik ortopedi el kitabı: editörler, Stephen A. Paget, Allan Gibofsky, John F. Beary; yardımcı editör Paul Pellicci; çeviri editörleri ; Dr. Yusuf Yazıcı, Dr. Doruk Erkan, Dr. Akgün İnce ; önsözler, Stephen A. Paget, Allan Gibofsky, Prof. Dr. Hasan Yazıcı by Paget, Stephen A, Gibofsky, Allan, Beary, John F, Pellicci, Paul, Yazıcı, Yusuf, Erkan, Doruk, İnce, Akgün

Get more information

US drug and biologic approvals in 1997 by Beary III, John F., Siegfried, John D., Tavares, Renee

“…The Prescription Drug User Fee Act of 1992 enhanced review resources for the Food and Drug Administration (FDA). The past two years have seen an unprecedented…”
Get full text

The Predictive Power of the Polygraph: The Lies Lie Detectors Tell by Phillips, Michael, Brett, Allan S, Beary, John F

“…To the Editor.—We were particularly interested by the recent report on the polygraph,1 and commend the Council on Scientific Affairs for presenting a…”
Get full text

U.S. drug and biologic approvals in 1994-1995 by Beary III, John F., Duchaine, Christina M., Rhein Jr, Reginald W.

“…Since the introduction of the Prescription Drug User Fee in 1992, the mean approval time for new drugs has decreased from 29.9 months (1992) to 19.2 months…”
Get full text

U.S. drug and biologic approvals in 1996 by Beary III, John F., Robillard, Lara E., Woollett, Gillian R., Siegfried, John D., White, Thomas X., Shriver, David A.

“…Since the introduction of the Prescription Drug User Fee Act of 1992, the mean approval time for new drugs has decreased from 29.9 months (1992) to 17.8 months…”
Get full text

Pediatric Injury and the Steel Jaw Trap by Beary, John F

“…To the Editor.—Pediatric textbooks routinely comment that accidents are the leading cause of death and morbidity in children and that most are preventable. I…”
Get full text